| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/22/2010 | WO2010044686A1 Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein |
| 04/22/2010 | WO2010044685A1 Nitrophenyl mustard alcohols, their corresponding phosphates and their use as targeted cytotoxic agents |
| 04/22/2010 | WO2010044585A2 Piperidine compounds, pharmaceutical composition comprising the same and its use |
| 04/22/2010 | WO2010044485A1 Alpha helix mimetics in the treatment of cancer |
| 04/22/2010 | WO2010044401A1 Morpholinopurine derivative |
| 04/22/2010 | WO2010043880A1 Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| 04/22/2010 | WO2010043867A1 Pyrrolo [2, 3-d] pyrimidines as inhibitors of hsp90 |
| 04/22/2010 | WO2010043866A2 Histone lysine demethylase inhibitors |
| 04/22/2010 | WO2010043865A1 Inhibitors of hsp90 |
| 04/22/2010 | WO2010043847A1 Medium derived from stem cells as a pharmaceutical composition |
| 04/22/2010 | WO2010043832A1 Novel pharmaceutical uses for nanoparticles |
| 04/22/2010 | WO2010043721A1 Oxidase inhibitors and their use |
| 04/22/2010 | WO2010043711A1 Allosteric protein kinase modulators |
| 04/22/2010 | WO2010043676A1 Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
| 04/22/2010 | WO2010043631A1 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy |
| 04/22/2010 | WO2010043186A1 New pt(ii) complex and antitumor activity thereof |
| 04/22/2010 | WO2010043180A1 Ethoxy diphenyl ethane derivates, preparation processes and uses thereof |
| 04/22/2010 | WO2010043050A1 Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| 04/22/2010 | WO2010043049A1 Etoposide and doxorubicin conjugates for drug delivery |
| 04/22/2010 | WO2010043037A1 Formulations targeting igfbp7 for diagnosis and therapy of cancer |
| 04/22/2010 | WO2010043029A1 Use of tetrose to inhibit cancer and to increase cell viability |
| 04/22/2010 | WO2010043000A1 S1p receptors modulators and their use thereof |
| 04/22/2010 | WO2010042998A1 S1p receptors modulators |
| 04/22/2010 | WO2010028156A8 Dual modality detection of apoptosis |
| 04/22/2010 | WO2010014176A3 Preparation method of biodegradable micro-particles containing drugs |
| 04/22/2010 | WO2010012466A8 Antitumor properties of no modified protease inhibitors |
| 04/22/2010 | WO2010011666A3 Indoline scaffold shp-2 inhibitors and cancer treatment method |
| 04/22/2010 | WO2010011325A3 Synthesis and utilization of small molecules for the treatment of inflammation associated with interleukin-1 signaling |
| 04/22/2010 | WO2010011319A8 Magnetic heating for drug delivery and other applications |
| 04/22/2010 | WO2010011296A3 Deacetylase inhibitors and uses thereof |
| 04/22/2010 | WO2010009985A3 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 04/22/2010 | WO2010006153A3 Topopyrones: dual topoisomerase inhibitors |
| 04/22/2010 | WO2010005726A3 Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| 04/22/2010 | WO2010005725A3 Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| 04/22/2010 | WO2010003313A8 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| 04/22/2010 | WO2009158309A3 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 04/22/2010 | WO2009155535A3 Compositions, methods and kits for eliciting an immune response |
| 04/22/2010 | WO2009153670A3 Antibodies against domains of laminin-332 |
| 04/22/2010 | WO2009151644A3 Small molecule inhibitors of autotaxin methods of use |
| 04/22/2010 | WO2009137660A3 Enhancement of drug therapy by mirna |
| 04/22/2010 | WO2009129545A8 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| 04/22/2010 | WO2009120905A3 Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| 04/22/2010 | WO2009112022A3 Pharmaceutical composition for the diagnosis or treatment of diseases associated with zinc finger proteins |
| 04/22/2010 | WO2009107098A3 An oral treatment composition comprising potassium nitrate and hexylene glycol |
| 04/22/2010 | WO2009043450A8 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 04/22/2010 | WO2009030092A9 Culture medium and method for in vitro culturing human adult primary mesenchymal stem cells on a large scale, primary mesenchymal stem cells obtained by the method, the uses thereof |
| 04/22/2010 | WO2009029601A3 Receptor-targeting reagents |
| 04/22/2010 | WO2009027706A3 Radiolabeled monomeric and multimeric cyclic oligopeptides binding to the cxcr4 receptor for cancer imaging and treatment |
| 04/22/2010 | WO2008140624A3 Methods and compositions related to hybird nanoparticles |
| 04/22/2010 | US20100100979 Biomarker specific for cancer |
| 04/22/2010 | US20100099843 Dolastatin 15 derivatives |
| 04/22/2010 | US20100099755 Chemotherapeutic flavonoids, and syntheses thereof |
| 04/22/2010 | US20100099748 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes |
| 04/22/2010 | US20100099746 Novel nucleic acid |
| 04/22/2010 | US20100099744 RNA INTERFERENCE MEDIATED INHIBITION OF MATRIX METALLOPROTEINASE 13 (MMP13) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/22/2010 | US20100099742 Sensitizing Cells for Apoptosis by Selectively Blocking Cytokines |
| 04/22/2010 | US20100099737 Compositions and methods for treating myelosuppression |
| 04/22/2010 | US20100099730 Annellated pyrrole compounds for cancer management |
| 04/22/2010 | US20100099726 Inhibitors of pyruvate kinase and methods of treating disease |
| 04/22/2010 | US20100099720 Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy |
| 04/22/2010 | US20100099711 Methods and Compositions Using Immunomodulatory Compounds for The Treatment and Management of Cancers and Other Diseases |
| 04/22/2010 | US20100099697 Method of Treatment Using Inhibitors of Mitosis |
| 04/22/2010 | US20100099694 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular ikk inhibitors |
| 04/22/2010 | US20100099691 Pyrimidinyl pyridone inhibitors of jnk |
| 04/22/2010 | US20100099689 Methods of modulating ppar gamma-type receptors |
| 04/22/2010 | US20100099688 Novel phosphodiesterase inhibitors |
| 04/22/2010 | US20100099686 Compounds useful as protein kinase inhibitors |
| 04/22/2010 | US20100099683 Compounds that inhibit human dna ligases and methods of treating cancer |
| 04/22/2010 | US20100099679 FUSED BICYCLIC mTOR INHIBITORS |
| 04/22/2010 | US20100099658 Di(arylamino)aryl compound |
| 04/22/2010 | US20100099657 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity |
| 04/22/2010 | US20100099654 Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents |
| 04/22/2010 | US20100099642 Tgf-beta stimulant and further agent to reduce side effects |
| 04/22/2010 | US20100099639 W/o/w emulsion composition |
| 04/22/2010 | US20100099638 Immunocompetent xenograft model |
| 04/22/2010 | US20100099628 Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue |
| 04/22/2010 | US20100099627 Nuclear targeting sequences |
| 04/22/2010 | US20100099626 Cell penetrating peptides for intracellular delivery of molecules |
| 04/22/2010 | US20100099617 Secreted proteins |
| 04/22/2010 | US20100099612 treating cancer responsive to interferon alpha therapy; the protein is non-naturally occurring and has enhanced anti-viral and anti-proliferative activity in comparison to human interferon alpha 2b (HuIFN- alpha 2b) |
| 04/22/2010 | US20100099604 Peptidic and non peptidic ligands for immunodetection of the receptor for urotensin |
| 04/22/2010 | US20100098774 Composition comprising crustacean gastrolith components and its use |
| 04/22/2010 | US20100098763 Pharmaceutical formulation 514 |
| 04/22/2010 | US20100098735 Injectable depot compositions and its process of preparation |
| 04/22/2010 | US20100098730 Immunoglobulin variants and uses thereof |
| 04/22/2010 | US20100098713 Drug screening; assay for aldehyde dehydrogenase activity; cancer |
| 04/22/2010 | US20100098710 Anti-IGF-1R Antibodies and Uses Thereof |
| 04/22/2010 | US20100098709 Antibodies Specific For The Complex Of Interleukin-6 And The Interleukin-6 Receptor |
| 04/22/2010 | US20100098706 Monoclonal antibody directed against the human ldl receptor |
| 04/22/2010 | US20100098702 Method of treating androgen independent prostate cancer |
| 04/22/2010 | US20100098701 Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| 04/22/2010 | US20100098694 Antibodies to cd40 |
| 04/22/2010 | US20100098692 Humanized Endoglin Antibodies |
| 04/22/2010 | US20100098691 Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| 04/22/2010 | US20100098690 Pharmaceutical composition |
| 04/22/2010 | US20100098687 Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions |
| 04/22/2010 | US20100098681 Dimeric high affinity egfr constructs and uses thereof |
| 04/22/2010 | US20100098680 Anti-pathogen treatments |
| 04/22/2010 | US20100098671 composition for prevention or treatment of bone marrow damage |
| 04/22/2010 | US20100098668 Oncolytic Adenoviruses and Uses Thereof |